

# Early SARS-CoV-2 Reinfections Involving the Same or Different Genomic Lineages, Spain

Cristina Rodríguez-Grande, Agustín Estévez, Rosalía Palomino-Cabrera, Andrea Molero-Salinas, Daniel Peñas-Utrilla, Marta Herranz, Amadeo Sanz-Pérez, Luis Alcalá, Cristina Veintimilla, Pilar Catalán, Carolina Martínez-Laperche, Roberto Alonso, Patricia Muñoz, Laura Pérez-Lago,<sup>1</sup> Darío García de Viedma,<sup>1</sup> on behalf of the Gregorio Marañón Microbiology-ID COVID 19 Study Group<sup>2</sup>

Centers for Disease Control and Prevention guidelines consider SARS-CoV-2 reinfection when sequential COVID-19 episodes occur  $\geq 90$  days apart. However, genomic diversity acquired over recent COVID-19 waves could mean previous infection provides insufficient cross-protection. We used genomic analysis to assess the percentage of early reinfections in a sample of 26 patients with 2 COVID-19 episodes separated by 20–45 days. Among sampled patients, 11 (42%) had reinfections involving different SARS-CoV-2 variants or sub-variants. Another 4 cases were probable reinfections; 3 involved different strains from the same lineage or sub-lineage. Host genomic analysis confirmed the 2 sequential specimens belonged to the same patient. Among all reinfections, 36.4% involved non-Omicron, then Omicron lineages. Early reinfections showed no specific clinical patterns; 45% were among unvaccinated or incompletely vaccinated persons, 27% were among persons <18 years of age, and 64% of patients had no risk factors. Time between sequential positive SARS-CoV-2 PCRs to consider reinfection should be re-evaluated.

**E**stimates of the burden of SARS-CoV-2 reinfections continue to be crucial for assessing new SARS-CoV-2 variants with immune escape potential (1). Genomic analysis of SARS-CoV-2 strains involved in sequential COVID-19 episodes has been key to

assessing the proportion of reinfections, differentiating reinfection from persistent infection, and characterizing reinfection in detail.

Centers for Disease Control and Prevention (CDC) guidelines for consideration of SARS-CoV-2 reinfection require evidence of 2 sequential COVID-19 episodes separated by  $\geq 90$  days and  $\geq 1$  negative RT-PCR in between (2). However, inclusion criterion for most studies that have focused on COVID-19 reinfection have usually required 45–60 days between sequential episodes (3,4). This timeframe maximizes factors that increase the likelihood of reinfection, including the chance of cure of the first episode, clearance of the strain involved in the first episode, and possibility of reexposure to another positive case. Following this philosophy, we reported a systematic population-based analysis of reinfections during the first, second, and third pandemic waves in Spain (5). Some studies conducted during Omicron waves described an increase in the proportion of reinfections (6,7) and a shorter interval between reinfection episodes, such as early reinfections in  $\leq 60$  days. In this study, we aimed to evaluate the possibility of finding reinfections when they are even less likely, <45 days between episodes, and assess which SARS-CoV-2 variants were involved. The study was

Author affiliations: Gregorio Marañón General University Hospital, Madrid, Spain (C. Rodríguez-Grande, A. Estévez, R. Palomino-Cabrera, A. Molero-Salinas, D. Peñas-Utrilla, M. Herranz, A. Sanz-Pérez, L. Alcalá, C. Veintimilla, P. Catalán, C. Martínez-Laperche, R. Alonso, P. Muñoz, L. Pérez-Lago, D. García de Viedma); Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid (C. Rodríguez-Grande, A. Estévez, R. Palomino-Cabrera, A. Molero-Salinas, D. Peñas-Utrilla, A. Sanz-Pérez, L. Pérez-Lago, D. García de Viedma); Universidad

Complutense, Madrid (R. Alonso, P. Muñoz); Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Respiratorias-CIBERES, Madrid (R. Alonso, P. Muñoz, D. García de Viedma)

DOI: <https://doi.org/10.3201/eid2906.221696>

<sup>1</sup>This senior authors contributed equally to this article.

<sup>2</sup>Additional members of the Gregorio Marañón Microbiology-ID COVID-19 Study Group who contributed data are listed at the end of this article.

based on the 15,794 COVID-19 cases diagnosed during November 26, 2021–August 21, 2022, at Gregorio Marañón General University Hospital, a tertiary hospital that serves 650,000 inhabitants in the population of Madrid, Spain.

## Material and Methods

### Specimens

We selected all cases with 2 sequential COVID-19 episodes at an interval of 20–45 days by considering the time between the last positive reverse transcription PCR (RT-PCR) specimen in the first episode and the first positive specimen in the second episode. We also requested cases for which  $\geq 1$  positive specimen was available in our stored collection, among those taken in the first 10 days of each sequential episode, and for which the specimens had sufficient viral load (cycle threshold [Ct]  $\leq 32$ ) to maximize the chance of obtaining optimal coverage in whole-genome sequence analysis. To minimize the possibility of including potentially persistent cases, we excluded cases that had clinical conditions or admissions to hospital services that likely corresponded to immunocompromised status.

We used remnants of nasopharyngeal swab specimens previously used for diagnostic purposes via TaqPath COVID-19 CE-IVD RT-PCR kit (ThermoFisher Scientific, <https://www.thermofisher.com>) during November 26, 2021–August 21, 2022. We extracted viral RNA from nasopharyngeal exudates by using the KingFisher instrument (ThermoFisher Scientific). We used 16  $\mu$ L of RNA as a template for reverse transcription by using LunaScript RT SuperMix Kit (New England Biolabs, <https://www.neb.com>).

### Whole-Genome Sequencing

We performed whole-genome amplification of SARS-CoV-2 (Appendix, <https://wwwnc.cdc.gov/EID/article/29/6/22-1696-App1.pdf>). We deposited sequences above the GISAID quality thresholds into the GISAID database (<https://www.gisaid.org>); we submitted sequences below the GISAID threshold to the European Nucleotide archive (<https://www.ebi.ac.uk/ena>; project no. PRJEB56460) (Appendix Tables 1–3).

We considered a case to be a reinfection if different lineages or sublineages were involved in each sequential episode. We also assigned cases as probable reinfections when the sequential strains belonged to the same lineage or sublineage and the sequential strains harbored specific single-nucleotide variants (SNVs) not shared between the first and second

episode, indicating that the sequence from the second episode was not derived from the first episode.

### Minority Variant Analysis

We assessed whether the strain involved in the first episode persisted as a minority variant (i.e., trace of the virus) in the second episode. In each early reinfection case, we used Integrative Genomics Viewer version 2.14.1 (Broad Institute, <https://www.broadinstitute.org>) to visually inspect SNV alleles called in the strain involved in the first episode in the sequences obtained from the strains involved in the second episode.

### Short Tandem Repeat Analysis


We conducted short tandem repeat analysis to ensure that the tested specimens from sequential episodes of all reinfection and probable reinfection cases belonged to the same patient. We used the Mentype Chimera PCR Amplification Kit (Biotype, <https://www.biotype.de>) to examine 12 noncoding short tandem repeat loci and the sex-specific amylogenic locus on specimens (Appendix).

## Results

The first Omicron variant in our study population was identified during late November 2021. Delta and Omicron variants coexisted during November 26, 2021–January 15, 2022. The study population yielded 66 (0.42%) cases with 2 sequential COVID-19 cases that fulfilled our criteria (Figure). From this initial selection, we excluded 23 cases with clinical conditions or hospitalizations that likely corresponded to an immunocompromised status to minimize the inclusion of potentially persistent cases. Of the remaining 43 cases, 29 had positive specimens in our stored collection representative of 2 sequential episodes that could be analyzed by WGS. For 26 cases (89.7%), we obtained sequences of optimal quality and good coverage from 2 sequential episodes that enabled us to perform a one-to-one genomic comparison of both sequences (Figure).

In 11 (42%) of the 26 cases, genomic analysis indicated that reinfection occurred and involved different lineages or sublineages in each episode (Figure). Among those 11 cases, 4 involved non-Omicron followed by Omicron variants (i.e., Delta to Omicron BA.1); 4 involved 2 different Omicron lineages (BA.1.17 to B.1.1.529, BA.5 to BA.1.1, BA.5 to BA.2, and BA.2.36 to BA.5.1); and 3 involved different Omicron sublineages (BA.1.17 and BA.1.1, 10 differential SNVs; BA.1 and BA.1.1, 8 SNVs; and BA.5.2 and BA.5.1, 13 SNVs).

We considered another 4 cases to be probable reinfections (Figure): 3 involved different strains from



**Figure.** Flowchart of case selection in a study of early SARS-CoV-2 reinfection involving the same or different genomic lineages, Spain. PCR-positive cases were diagnosed by our tertiary hospital, which covers 650,000 inhabitants in the population of Madrid. Among 26 cases with optimal coverage for WGS, 11 were reinfections (red boxes), 4 of which were non-Omicron to Omicron lineage reinfections. Probable reinfection cases (yellow boxes; patients 23–26) showed enough unique SNV differences between the sequences from their sequential specimens to be suspect of reinfection (Appendix Table 3, <https://wwwnc.cdc.gov/EID/article/29/6/22-1696-App1.pdf>). Ct, cycle threshold; SNV, single-nucleotide variants; WGS, whole-genome sequencing.

the same sublineage (BA.2, BA.1.1, and BA.1.17); in the fourth case (case 26), we were unable to assign the variant in 1 of the specimens. In all 4 cases, we observed differential SNVs (4–8 SNVs) between the sequences from the sequential episodes. All the differential SNV calls between the sequential episodes were robust, as indicated by the good sequencing coverage (73–2,847 nt depth) observed in those positions (Appendix Table 3). The distribution of the differential SNVs between the sequential sequences in these cases pointed to independent evolutionary pathways; 1–4 SNVs in the first episode were absent in the second, and 3–5 SNVs in the second episode were absent in the first. Those observations ruled out the possibility that the sequence from the second episode evolved from the first sequence, thus indicating that 2 unrelated strains were involved in each of the sequential episodes.

Because of the short time between COVID-19 episodes in our study, we assessed whether the strain involved in the first episode of early reinfected cases could still be traced as remnant minority variants in the second episode. A thorough visual review of SNVs called in the second episode did not identify any minority calls corresponding to SNVs identified

in the first episode strain, which indicated that the strain involved in the first episode had been cleared by the time the second infection was established.

We further refined the characterization of reinfections by also performing host genomic characterization to clean up any laboratory errors and ensure that the sequential specimens belonged to the same patient. We performed short tandem repeat analysis on specimens from 15 of 16 cases assigned as reinfections or probable reinfections. For all 15 cases, host genetic analysis confirmed that the 2 sequential specimens used in the study belonged to the same patient. For the remaining 1 case (case 10), no host material was available.

A review of the clinical characteristics of the 11 cases of early SARS-CoV-2 reinfections did not suggest a specific pattern: 63.6% were among female patients, patient ages were 8–88 years, 36.4% of patients had not been vaccinated, and 9.1% had incomplete vaccination schedules (Table 1). Among the unvaccinated case-patients, most were young (8–29 years of age). In most (54.5%) reinfections, symptoms were mild, and 5 patients were asymptomatic. Relevant risk factors were high blood pressure (27.3%), heart disease (18.2%), diabetes (18.2%), and previous ictus

(18.3%). In 50% of cases, a SARS-CoV-2 RT-PCR was requested before a procedure or intervention at the hospital or after exposure to a COVID-19 case (Table 2). SARS-CoV-2 antibody serology testing was not available before the first episode for all but 2 cases (cases 10 and 11), but in those cases, serologic results were negative. None of the patients died.

Among the 4 probable reinfections, patient ages were 58–81 years, 2 were male, and 3 had a full vaccination schedule before the first COVID-19 episode (Table 2). Three of the probable reinfections were asymptomatic, but we have no clinical information regarding the COVID-19 episode in the fourth patient. Relevant risk factors were high blood pressure (100%), diabetes (75%), chronic kidney disease (50%), and heart disease (50%).

Another 11 cases in the analysis were not reinfections but short-term persistence involving the same strain. The evolution of the Ct values in those cases was consistent with persistence because most (82%) had higher Ct in the second specimen; 2 had Ct values that were not markedly lower, 3 and 8 cycles difference. The strains corresponded to the Omicron variant and either had acquired no diversity, had 0 SNVs between sequential isolates, or had 1–5 SNVs in the second specimen, consistent with an acquisition of diversity by microevolution during the persistence period. We also reviewed the clinical charts for those case-patients (Table 3); their ages were 1–94 years and 63.6% were female. The most prevalent risk factors were high blood pressure (54.5%), overweight or obesity (54.5%), heart disease (45.5%), and autoimmune diseases (27.3%). Compared with patients who had short-term SARS-CoV-2 persistence, early reinfected patients were younger (43.3 vs. 58.5 years) and had lower baseline pathology (36.4% vs. 72.7%). In terms of clinical severity, 36.4% of patients with early reinfection were asymptomatic in the first episode and 45.5% were asymptomatic in the second episode, compared with only 18.2% of case-patients who had short-term persistence. For the early reinfection group, despite being statistically nonsignificant, the second episode tended to be less severe; in only 3 cases, the second episode was more severe than the first. Among early reinfections, 18.2% of case-patients required hospital admission for COVID-19 during the first episode and none required hospitalization for the second episodes, compared with 27.3% of patients with short-term persistence who required hospitalization. One (9.1%) patient in the short-term persistence group died due to COVID-19 versus none in the early reinfection group.

**Table 1.** Clinical characteristics of patients with early SARS-CoV-2 reinfection involving the same or different genomic lineages, Spain\*

| Characteristics                           | First episode, n = 11 | Second episode, n = 11 |
|---|-----------------------|------------------------|
| Average age, y (range)                    | 43.27 (8–88)          | 43.27 (8–88)           |
| Sex                                       |                       |                        |
| M   | 4 (36.36)             | 4 (36.36)              |
| F   | 7 (63.64)             | 7 (63.64)              |
| Illness severity                          |                       |                        |
| Asymptomatic                              | 4 (36.36)             | 5 (45.45)              |
| Mild                                      | 5 (45.45)             | 6 (54.55)              |
| Intermediate                              | 2 (18.18)             | 0                      |
| Severe                                    | 0                     | 0                      |
| Care required                             |                       |                        |
| Emergency                                 | 0                     | 0                      |
| Hospital admission                        | 3 (27.27)             | 2 (18.18)              |
| Hospital admission for COVID-19           | 2 (18.18)             | 0                      |
| Nosocomial transmission                   | 1 (9.09)              | 0                      |
| ICU                                       | 0                     | 0                      |
| ICU for COVID-19                          | 0                     | 0                      |
| Underlying conditions                     |                       |                        |
| None of interest                          | 7 (63.64)             | 7 (63.64)              |
| High blood pressure                       | 3 (27.27)             | 3 (27.27)              |
| COPD                                      | 1 (9.09)              | 1 (9.09)               |
| Asthma                                    | 0                     | 0                      |
| Diabetes                                  | 2 (18.18)             | 2 (18.18)              |
| Ictus                                     | 2 (18.18)             | 2 (18.18)              |
| Overweight/obesity                        | 1 (9.09)              | 1 (9.09)               |
| Heart disease                             | 2 (18.18)             | 2 (18.18)              |
| Autoimmune                                | 1 (9.09)              | 1 (9.09)               |
| Oncological                               | 0                     | 0                      |
| Chronic kidney disease                    | 1 (9.09)              | 1 (9.09)               |
| HIV infection                             | 0                     | 0                      |
| AIDS                                      | 0                     | 0                      |
| Pregnant                                  | 0                     | 0                      |
| Paxlovid use‡                             | 0                     | 0                      |
| Use of dexamethasone                      | 0                     | 0                      |
| Death                                     | 0                     | 0                      |
| Vaccines and serology                     |                       |                        |
| Complete vaccination schedule             | 6 (54.55)             | 6 (54.55)              |
| Incomplete vaccination schedule           | 1 (9.09)              | 1 (9.09)               |
| Unvaccinated                              | 4 (36.36)             | 4 (36.36)              |
| Previous positive serology for SARS-CoV-2 | 0                     | 0                      |
| Previous negative serology for SARS-CoV-2 | 2 (18.18)             | 2 (18.18)              |
| Serology not available                    | 9 (81.82)             | 9 (81.82)              |

\*Values are no. (%) except as indicated. COPD, chronic obstructive pulmonary disease; ICU, intensive care unit.

†Illness severity was defined according to the following criteria: mild, general unrest, cough, diarrhea, cephalgia, fever, anosmia, myalgias, rhinorrhea; moderate, previous symptoms plus dyspnea, mild respiratory failure, or unilateral pneumonia; severe, previously listed symptoms plus bilateral pneumonia or severe respiratory failure.

‡Nirmatrelvir/ritonavir.

## Discussion

Most studies focusing on COVID-19 reinfections followed the CDC guidelines during the first waves of the pandemic (8). Nevertheless, the guidelines need to be reviewed in the current epidemiologic context, which is substantially different from when most reinfection studies were conducted. One crucial



difference is the emergence of the Omicron variant at the end of 2021. Omicron is markedly different from previous variants, harboring a constellation of >55 mutations, 32 of which are in the spike, and 15 mutations map to the receptor-binding domain. Those mutations triggered alarm about the possibility of immune escape from the protection conferred by pre-Omicron variant infections. Those suspicions were confirmed, and Omicron was shown to be barely neutralized by serum from convalescent patients (9).

The lack of Omicron neutralization during *in vitro* exposure to serum from vaccinated or convalescent case-patients infected with earlier variants led to consideration that reinfections were likely to increase.

A large study in South Africa demonstrated that risk assessments for reinfection with Omicron were higher than for pre-Omicron variants (7). Similarly, the 6.8% reinfection rate with Omicron in Marseille, France, was markedly higher than infection rates (0.2%–1.5%) in pre-Omicron pandemic waves (6).

If Omicron escapes the protection associated with infection from earlier variants, then higher rates of Omicron reinfection could be expected to occur within a shorter time after the first episode (i.e., early reinfections) than was seen with previous variants. This shorter reinfection time was noted in Italy (10), where Omicron reinfections occurred 25–60 days after the first COVID-19 episode involving the Delta variant,

**Table 2.** Clinical characteristics of patients with early SARS-CoV-2 reinfection or probable reinfection involving the same or different genomic lineages, Spain\*

| Pt. no.                      | Age, y/sex | Underlying conditions           | Illness severity, 1st/2nd episode† | COVID-19 care required, 1st/2nd episode | COVID-19 treatment | Vaccine schedule             | Inter-infection period, d | PCR Ct, 1st/2nd episode | Reason for PCR, 1st/2nd episode | SARS-CoV-2 variant, 1st/2nd episode |
|------------------------------|------------|---------------------------------|------------------------------------|---|--------------------|------------------------------|---------------------------|-------------------------|---------------------------------|-------------------------------------|
| <b>Reinfections</b>          |            |                                 |                                    |   |                    |                              |                           |                         |                                 |                                     |
| 1                            | 29/M       | None                            | Mild/mild                          | N/N                                     | N                  | N                            | 37                        | 24/22                   | Symp/symp                       | AY.127/BA.1.1.1                     |
| 2                            | 12/M       | None                            | Mild/mild                          | N/N                                     | N                  | N                            | 34                        | 30/19                   | Symp/symp                       | AY.124/BA.1.1                       |
| 3                            | 8/F        | None                            | Asymp/mild                         | N/N                                     | N                  | N                            | 37                        | 30/22                   | PE/symp                         | B.1.617.2 Delta plus/BA.1.1         |
| 4                            | 85/F       | HBP, DM, obesity                | Asymp/mild                         | N/N                                     | N                  | Complete, Pfizer             | 41                        | 32/25                   | PP/PE                           | BA.1.17/BA.1.1                      |
| 5                            | 27/F       | None                            | Mild/asymp                         | N/N                                     | N                  | Complete, AstraZeneca/Pfizer | 42                        | 22/32                   | PP/PP                           | BA.1.17/B.1.1.529                   |
| 6                            | 28/F       | None                            | Asymp/mild                         | N/N                                     | N                  | Complete, Pfizer/Moderna     | 27                        | 32/16                   | PE/symp                         | BA.1/BA.1.1                         |
| 7                            | 42/F       | None                            | Mild/mild                          | N/N                                     | N                  | Incomplete, Pfizer           | 41                        | 32/20                   | Symp/symp                       | AY.122/BA.1.17                      |
| 8                            | 11/F       | None                            | Asymp/asymp                        | N/N                                     | N                  | N                            | 22                        | 30/27                   | PP/PP                           | BA.2.36/BA.5.1                      |
| 9                            | 88/M       | COPD, ictus, heart disease, CKD | Mod/asymp                          | Hospital admission/N                    | Steroids           | Complete, Pfizer             | 25                        | 13/26                   | Symp/PP                         | BA.5/BA.2                           |
| 10                           | 63/F       | HBP, systemic sclerosis         | Mild/asymp                         | N/N                                     | N                  | Incomplete, AstraZeneca      | 20                        | 19/32                   | Symp/PP                         | BA.5/BA.1.1                         |
| 11                           | 83/M       | HBP, DM, ictus, heart disease   | Mod/asymp                          | Hospital admission/N                    | Steroids           | Complete, Pfizer             | 27                        | 16/32                   | Symp/PP                         | BA.5.2/BA.5.1                       |
| <b>Probable reinfections</b> |            |                                 |                                    |   |                    |                              |                           |                         |                                 |                                     |
| 23                           | 74/F       | HBP, DM, heart disease          | NA/NA                              | NA/NA                                   | NA                 | Complete, Pfizer             | 21                        | 31/16                   | NA/NA                           | BA.2/BA.2                           |
| 24                           | 81/M       | HBP, DM, heart disease, CKD     | Mod/asymp                          | Hospital admission/hospital admission   | Steroids           | Complete, Pfizer             | 45                        | 22/30                   | Symp/PP                         | BA.1.1/BA.1.1                       |
| 25                           | 64/F       | HBP, CKD                        | Mild/asymp                         | Emergency/N                             | N                  | Incomplete, Pfizer           | 26                        | 32/30                   | Symp/symp                       | BA.1.17/BA.1.17                     |
| 26                           | 58/M       | HBP, DM                         | Asymp/asymp                        | N/N                                     | N                  | Complete, Pfizer             | 24                        | 29/30                   | PP/PP                           | BA.2/unassigned                     |

\*Asymp, asymptomatic; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HBP, high blood pressure; ICU, intensive care unit; NA, not available; PP, pre-procedure; PE, postexposure; symp, symptoms.

†Severity of illness was defined according to the following criteria: mild, general unrest, cough, diarrhea, headache, fever, anosmia, dysgeusia, myalgia, rhinorrhea; Moderate, the above symptoms plus dyspnea, mild respiratory failure, or unilateral pneumonia; Severe, the above symptoms plus bilateral pneumonia or unilateral pneumonia with respiratory failure.

whereas reinfections involving Omicron in both sequential episodes (BA.1 to BA.2) were identified within the standard time range for reinfection,  $\geq 90$  days. Likewise, in Belgium, most early reinfections ( $< 60$  days) identified involved Omicron after a Delta infection (11). Other studies have also reported shorter times (24 days and 39 days) between episodes involving non-Omicron to Omicron reinfections (11,12).

To identify early non-Omicron followed by Omicron infections and classify variants as Omicron or non-Omicron, many previous studies relied on indirect inference methods, not WGS. In one study, spike gene target failure, which could be detected in Delta but not Omicron in the TaqPath RT-PCR, was used as a proxy marker to assign the variant (11). In another study, variants of concern (VOCs) were inferred by determining changes in the melting patterns of probes used in RT-PCR to target regions where marker SNVs are located (4). Although such inferences are useful and practicable, they can only assign reinfections involving certain VOCs, thereby missing possible early reinfections involving the same lineages or even sub-lineages, which can only be addressed by WGS characterization.

In our study, we tried to optimize the characterization of early reinfections in the Omicron era by performing WGS to cover all possible variants involved, narrowing the time range between episodes to  $< 45$  days to capture the earliest reinfections, and fine-tuning the analysis as much as possible by host genetic analysis to ensure that the 2 sequential specimens used for genomic viral comparison belonged to the same patient. During the study period, we detected a total of 66 (0.42%) cases with sequential RT-PCR-positive specimens in an interval of 20–45 days. That percentage was higher than the cases with sequential positives 45–90 days (8 cases, 0.05%) or  $> 90$  days (38 cases, 0.24%) apart.

One relevant finding was that among suspected cases of early reinfection, we confirmed early reinfection in 38% (11/29) of cases with specimens available for sequencing. In addition, the time interval between episodes was very short, 20–42 days. A recent systematic review on SARS-CoV-2 reinfections also determined a period of 23–57 days for reinfections (8), below the standard 90-day threshold, despite including data from studies published before May 22, 2022; data from the latest waves were also probably under-represented. More recent criteria for considering reinfections enable reduction to  $\geq 45$  days between episodes for persons with symptoms, evidence of close contact with a confirmed case, and no evidence of other causes of infection (2). Our data indicate that

**Table 3.** Clinical characteristics of case-patients with short-term SARS-CoV-2 persistence in study of early SARS-CoV-2 reinfection involving the same or different genomic lineages, Spain\*

| Characteristic                            | Value, n = 11 |
|---|---------------|
| Average age, y (range)                    | 58.5 (1–94)   |
| Sex                                       |               |
| M   | 4 (36.4)      |
| F   | 7 (63.6)      |
| Illness severity                          |               |
| Asymptomatic                              | 2 (18.2)      |
| Mild                                      | 4 (36.4)      |
| Intermediate                              | 2 (18.2)      |
| Severe                                    | 2 (18.2)      |
| Care required                             |               |
| Emergency                                 | 1 (9.1)       |
| Hospital admission                        | 6 (54.5)      |
| Hospital admission for COVID-19           | 3 (27.3)      |
| Nosocomial transmission                   | 1 (9.1)       |
| ICU                                       | 0             |
| ICU for COVID-19                          | 0             |
| Underlying conditions                     |               |
| None of interest                          | 3 (27.3)      |
| High blood pressure                       | 6 (54.5)      |
| COPD                                      | 2 (18.2)      |
| Asthma                                    | 1 (9.1)       |
| Diabetes                                  | 0             |
| Ictus                                     | 1 (9.1)       |
| Overweight/obesity                        | 6 (54.5)      |
| Heart disease                             | 5 (45.5)      |
| Autoimmune                                | 3 (27.3)      |
| Oncological                               | 2 (18.2)      |
| Chronic kidney disease                    | 2 (18.2)      |
| HIV infection                             | 1 (9.1)       |
| AIDS                                      | 0             |
| Pregnant                                  | 0             |
| Paxlovid use†                             | 1 (9.1)       |
| Remdesivir use                            | 3 (27.3)      |
| Tocilizumab use                           | 1 (9.1)       |
| Dexamethasone use                         | 4 (36.4)      |
| Death                                     | 1 (9.1)       |
| Vaccines and serology                     |               |
| Complete vaccination schedule             | 8 (72.7)      |
| Incomplete vaccination schedule           | 1 (9.1)       |
| Unvaccinated                              | 2 (18.2)      |
| Previous positive serology for SARS-CoV-2 | 3 (27.3)      |
| Previous negative serology for SARS-CoV-2 | 2 (18.2)      |
| Serology not available                    | 6 (54.5)      |

\*Values are no. (%) except as indicated. COPD, chronic obstructive pulmonary disease; ICU, intensive care unit.

†Illness severity was defined according to the following criteria: mild, general unrest, cough, diarrhea, cephalgia, fever, anosmia, myalgias, rhinorrhea; moderate, previous symptoms plus dyspnea, mild respiratory failure, or unilateral pneumonia; severe, previously listed symptoms plus bilateral pneumonia or severe respiratory failure.

‡Nirmatrelvir/ritonavir.

even those updated guidelines would miss the early reinfections that we highlight, and these combined findings should lead to reconsideration of the more stringent and longer period of  $\geq 90$  days between episodes used in the CDC guidelines.

About one third (36.4%) of the early reinfections in our study involved sequential infection with non-Omicron followed by Omicron variants, which is consistent with previous descriptions of Omicron

variants capable of causing immediate reinfection of patients newly recovered from COVID-19 (9). However, because of our nontargeted WGS-based design, we were able to identify not only early reinfections involving non-Omicron followed by Omicron variants but also reinfections with different Omicron lineages, different sublineages belonging to the same Omicron lineage, and even different strains from the same sublineage that were missed in other studies that used indirect inference methods. Our findings support reformulating the assumption that early infections are mainly restricted to a non-Omicron–Omicron alternation, because of the lack of cross-protection caused by major Omicron genetic differences.

Among the 4 probable early reinfections in our study, 3 cases involved 2 strains from the same sublineage. One case (case 23) constituted one of the shortest time intervals between episodes, 21 days apart, which contrasts with other studies that only found reinfections with the same variant for episodes  $\geq 90$  days apart. This probable early reinfection showed 8 SNVs between strains from the same lineage in the 2 separate episodes. In addition, several observations led us to reinforce its assignment as an early reinfection. First, the patient had 3 RT-PCR–negative specimens between the 2 RT-PCR–positive specimens 21 days apart, which sustains the hypothesis of early reinfection versus the alternative explanation of persistence. Second, the Ct value of the second specimen was 16, whereas the Ct of the first specimen was 31. We generally expect an increased Ct value, or reduced viral load, for a second specimen in cases of persistence, but a new reinfection should correspond to a lower Ct value, as noted in that case. Third, for persistence we expect a sequential acquisition of SNVs from the first strain during the persistence period. To the contrary, in that case, when we analyzed the distribution of the 8 SNVs identified between the 2 sequential specimens, 4 SNVs were only identified in the first specimen and another 4 were identified only in the second specimen, which is more consistent with the involvement of 2 independent strains, each with 4 proper SNVs.

The robustness of our assignment of early reinfections is supported by the precautionary consideration of the possibility of specimens belonging to different persons could be mishandled or misclassified, thereby leading to erroneous assignment as reinfections (13). However, we confirmed the hosts in all our reinfections by performing host analysis. Most of the literature focused on COVID-19 reinfections, with just a few exceptions (5,13,14), lacks host control.

We identified no common clinical pattern among early reinfection cases by sex, age, risk factors, or clinical conditions. Although we did not achieve strong statistical support because of our small sample size, we observed a tendency for the second episode in early reinfections to be equally or less severe than the previous episode. Of note, more than half (63.6%) of the reinfections were cases with no clinical history, which means that we need to broaden the circumstances for suspecting early reinfections.

In our analysis, despite the efforts to minimize the interference of persistence in case selection by ruling out cases with positive PCRs between episodes and patients with immunosuppression, we still identified 11 cases in which the same strain was found in the 2 sequential episodes, even though 27.3% of those cases had no clinical history to justify persistence. Although those were cases of short-term persistence, our findings could help expand clinical patterns to consider unexpected persistence, which is different from long-term persistence that occurs mainly in immunosuppressed persons (15,16). Despite the short-term nature of such persistence, the findings could still be relevant, depending on clinical interpretations and isolation measures.

Our data fill a gap in observations of the time range between sequential COVID-19 episodes that has generally been missing from the literature. In addition, our study period covered the 6th, most recent, COVID-19 wave, to provide new information on reinfections in a scenario in which SARS-CoV-2 VOCs are emerging and the population has extensive vaccine coverage. To reinforce the robustness of our findings, we also provided additional analytical rigor and refinement by including host genetic analysis in the assignment of reinfection.

In conclusion, our study provides new data on early reinfections involving Omicron and other variants. These findings shorten the time between episodes in which reinfection can occur and broaden the clinical profile for reinfection beyond unvaccinated young persons. We showed that early reinfections are not exclusively associated with the impaired protection expected of a non-Omicron to Omicron sequence but also can involve very similar strains. Because early reinfection can occur in various clinical and epidemiologic circumstances, guidelines for assigning reinfection to only  $\geq 90$  days between sequential SARS-CoV-2–positive PCRs should be reevaluated.

Additional members of Gregorio Marañón Microbiology-ID COVID 19 Study Group: Teresa Aldámiz, Ana Álvarez-Uría, Elena Bermúdez, Emilio Bouza, Sergio Buenestado-Serrano, Almudena Burillo, Raquel Carrillo, Emilia

Cercenado, Alejandro Cobos, Cristina Díez, Pilar Escribano, Chiara Fanciulli, Alicia Galar, M<sup>a</sup> Dolores García, Paloma Gijón, Helmuth Guillén, Jesús Guinea, Álvaro Irigoyen, Martha Kestler, Juan Carlos López, Marina Machado, Mercedes Marín, Pablo Martín-Rabadán, Pedro Montilla, Belén Padilla, María Palomo, María Jesús Pérez-Granda, Leire Pérez, Elena Reigadas, Cristina Rincón, Belén Rodríguez, Sara Rodríguez, Adriana Rojas, María Jesús Ruiz-Serrano, Carlos Sánchez, Mar Sánchez, Julia Serrano, Francisco Tejerina, Maricela Valerio, M<sup>a</sup>, Lara Vesperinas, Teresa Vicente, and Sofía de la Villa.

### Acknowledgments

We thank the Genomics Unit of Gregorio Marañón University Hospital for support in the sequencing runs. We thank Janet Dawson for her help in editing and proofreading.

This work was supported by Instituto de Salud Carlos III (project no. PI21/01823) together with the FEDER fund “A way of making Europe,” and by the European Centre for Disease Prevention and Control (project no. 2021/PHF/23776), and Instituto de Investigación Sanitaria Gregorio Marañón (project no. 2021-II-PI-01). Additional funding from the Miguel Servet contract (no. CPII20/0000175) to L.P.L. and Predoctoral de Formación en Investigación en Salud contract (no. FI20/00129) to C.R.G.

### About the Author

Ms. Rodríguez-Grande is a PhD candidate at Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. Her research interests include molecular and genomic epidemiology of tuberculosis and SARS-CoV-2.

### References

- Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. *Nature*. 2022;602:671–5. <https://doi.org/10.1038/s41586-021-04389-z>
- Centers for Disease Control and Prevention. Investigative criteria for suspected cases of SARS-CoV-2 reinfection (ICR) [cited 2022 Nov 4]. <https://www.cdc.gov/coronavirus/2019-ncov/php/invest-criteria.html#print%0Ahttps://www.cdc.gov/coronavirus/2019-ncov/php/invest-criteria.html>
- Flacco ME, Acuti Martellucci C, Baccolini V, De Vito C, Renzi E, Villari P, et al. Risk of reinfection and disease after SARS-CoV-2 primary infection: meta-analysis. *Eur J Clin Invest*. 2022;52:e13845. <https://doi.org/10.1111/eci.13845>
- Vera-Lise I, Dominik E, Elisabeth R, Kerstin H, Raffael F, Angelika X, et al. “Rapid reinfections with different or same Omicron SARS-CoV-2 sub-variants.” *J Infect*. 2022;85:e96–8. <https://doi.org/10.1016/j.jinf.2022.07.003>
- Rodríguez-Grande C, Alcalá L, Estévez A, Sola-Campoy PJ, Buenestado-Serrano S, Martínez-Laperche C, et al.; Gregorio Marañón Microbiology-ID COVID 19 Study Group. Systematic genomic and clinical analysis of severe acute respiratory syndrome coronavirus 2 reinfections and recurrences involving the same strain. *Emerg Infect Dis*. 2022;28:85–94. <https://doi.org/10.3201/eid2801.211952>
- Nguyen NN, Houhamdi L, Hoang VT, Stoupan D, Fournier PE, Raoult D, et al. High rate of reinfection with the SARS-CoV-2 Omicron variant. *J Infect*. 2022;85:174–211. <https://doi.org/10.1016/j.jinf.2022.04.034>
- Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. *Science*. 2022;376(6593):eabn4947. <https://doi.org/10.1126/science.abn4947>
- Toro-Huamanchumo CJ, Hilario-Gomez MM, Pinedo-Castillo L, Zumarán-Nuñez CJ, Espinoza-Gonzales F, Caballero-Alvarado J, et al. Clinical and epidemiological features of patients with COVID-19 reinfection: a systematic review. *New Microbes New Infect*. 2022;48:101021. <https://doi.org/10.1016/j.nmni.2022.101021>
- Carreño JM, Alshammary H, Tcheou J, Singh G, Raskin AJ, Kawabata H, et al.; PSP-PARIS Study Group. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. *Nature*. 2022;602:682–8. <https://doi.org/10.1038/s41586-022-04399-5>
- Mencacci A, Gili A, Camilloni B, Bicchieraro G, Spaccapelo R, Bietta C, et al. Immediate reinfection with Omicron variant after clearance of a previous SARS-CoV-2 infection. *J Infect Public Health*. 2022;15:983–5. <https://doi.org/10.1016/j.jiph.2022.07.013>
- Nevejan L, Cuypers L, Laenen L, Van Loo L, Vermeulen F, Wollants E, et al. Early SARS-CoV-2 reinfections within 60 days and implications for retesting policies. *Emerg Infect Dis*. 2022;28:1729–31. <https://doi.org/10.3201/eid2808.220617>
- Seid AG, Yirko T, Sayeed S, Pliapat N. Infection with SARS-CoV-2 Omicron variant 24 days after non-Omicron infection, Pennsylvania, USA. *Emerg Infect Dis*. 2022;28:1911–3. <https://doi.org/10.3201/eid2809.220539>
- Pérez-Lago L, Machado M, Herranz M, Sola-Campoy PJ, Suárez-González J, Martínez-Laperche C, et al.; Gregorio Marañón Microbiology-ID COVID-19 Study Group. Host genetic analysis should be mandatory for proper classification of COVID-19 reinfections. *Open Forum Infect Dis*. 2021;8:ofab402. <https://doi.org/10.1093/ofid/ofab402>
- Tillet RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. *Lancet Infect Dis*. 2021;21:52–8. [https://doi.org/10.1016/S1473-3099\(20\)30764-7](https://doi.org/10.1016/S1473-3099(20)30764-7)
- Pérez-Lago L, Aldámiz-Echevarría T, García-Martínez R, Pérez-Latorre L, Herranz M, Sola-Campoy PJ, et al.; on behalf of Gregorio Marañón Microbiology-ID Covid Study Group. Different within-host viral evolution dynamics in severely immunosuppressed cases with persistent SARS-CoV-2. *Biomedicine*. 2021;9:808. <https://doi.org/10.3390/biomedicine9070808>
- Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman MA, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. *J Infect Dis*. 2021;223:23–7. <https://doi.org/10.1093/infdis/jiaa666>

Address for correspondence: Laura Pérez-Lago or Darío García de Viedma; Hospital General Universitario Gregorio Marañón, Dr. Esquerdo 46, Madrid 28007, Spain; email: lperezg00@gmail.com or dgvedma2@gmail.com



Article DOI: <https://doi.org/10.3201/eid2906.221696>

*EID cannot ensure accessibility for supplementary materials supplied by authors. Readers who have difficulty accessing supplementary content should contact the authors for assistance.*

# Early SARS-CoV-2 Reinfections Involving the Same or Different Genomic Lineages, Spain

## Appendix

### Whole-Genome Sequencing

Whole genome amplification of SARS-CoV-2 was done with Artic\_nCov-2019\_V4 and V4.1 primer panels (Integrated DNA Technologies, Inc., <https://www.idtdna.com>) (<https://artic.network/ncov-2019>) and Q5 Hot Start DNA polymerase (New England Biolabs, <https://www.neb.com>). Libraries were prepared using the Nextera DNA Flex Library Prep Kit (Illumina, <https://www.illumina.com>) and sequenced in pools on MiSeq equipment (2 × 150 bp).

Sequences above the GISAID quality thresholds were deposited in GISAID (<https://www.gisaid.org>) and those below the GISAID thresholds were submitted to ENA (PRJEB56460) (Appendix Table 1). An in-house analysis pipeline was applied to the sequencing reads ([https://github.com/MG-IiSGM/covid\\_multianalysis](https://github.com/MG-IiSGM/covid_multianalysis)). In brief, the pipeline involves the following 4 steps: 1) pre-processing and quality assessment of fastq files using fastp version 0.20.1 (<https://doi.org/10.1093/bioinformatics/bty560>) and fastQC version 0.11.9 (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc>); 2) mapping with BWA version 0.7.17 (<https://arxiv.org/abs/1303.3997>) and variant calling using iVar version 1.3.1 (<https://doi.org/10.1186/s13059-018-1618-7>); the wild type SARS-CoV-2 sequence (GenBank accession no. NC\_045512.2) was used as reference; 3) genome annotation with SnpEff version 5.1 (<https://doi.org/10.4161/fly.19695>) and wild type SARS-CoV-2 as reference, and lineage designation with Pangolin version 4.0.2 (<https://github.com/cov-lineages/pangolin>); and 4) calibration of occasional low coverage positions using joint variant calling.

## **Short Tandem Repeat Analysis**

Short Tandem Repeat (STR) analysis was applied for human identity testing and to ensure that the tested specimens from sequential episodes of reinfection cases belonged to the same patient. The Mentype Chimera PCR amplification kit (Biotype, Germany) was used on the specimens used for SARS-CoV-2 genome sequencing. We examined 12 non-coding STR loci and the sex-specific amelogenin locus, labeled with 3 different dyes (6-FAM, BTG, or BTY). PCR was performed with 0.2–1 ng of genomic DNA using the Mentype Chimera PCR amplification kit (Biotype, Germany), the GeneAmp PCR System 9700 Thermal Cycler, followed by capillary electrophoresis on the 3030x1 Genetic Analyzer (ThermoFisher Scientific, MA, USA), according to the manufacturers' instructions.

**Appendix Table 1.** Sequences deposited in GISAID and ENA from a study of early SARS-CoV-2 reinfection involving the same or different genomic lineages, Spain\*

| Patient no. | Episode no. | GISAID/ENA ID    |
|-------------|-------------|------------------|
| 1           | 1           | EPI_ISL_15213997 |
|             | 2           | EPI_ISL_15214010 |
| 2           | 1           | EPI_ISL_15214032 |
|             | 2           | EPI_ISL_15214024 |
| 3           | 1           | ERR10307499      |
|             | 2           | EPI_ISL_15214011 |
| 4           | 1           | EPI_ISL_15214044 |
|             | 2           | EPI_ISL_15214009 |
| 5           | 1           | EPI_ISL_15214013 |
|             | 2           | EPI_ISL_15214025 |
| 6           | 1           | EPI_ISL_15214029 |
|             | 2           | EPI_ISL_15214020 |
| 7           | 1           | ERR10307501      |
|             | 2           | EPI_ISL_15214014 |
| 8           | 1           | EPI_ISL_15214004 |
|             | 2           | EPI_ISL_13577683 |
| 9           | 1           | EPI_ISL_15214039 |
|             | 2           | EPI_ISL_15214027 |
| 10          | 1           | EPI_ISL_15214031 |
|             | 2           | EPI_ISL_15214018 |
| 11          | 1           | EPI_ISL_15214008 |
|             | 2           | EPI_ISL_15214033 |
| 12          | 1           | EPI_ISL_8306944  |
|             | 2           | EPI_ISL_15214012 |
| 13          | 1           | EPI_ISL_15214045 |
|             | 2           | EPI_ISL_15214019 |
| 14          | 1           | EPI_ISL_8926943  |
|             | 2           | EPI_ISL_15214042 |
| 15          | 1           | EPI_ISL_13476995 |
|             | 2           | EPI_ISL_13476918 |
| 16          | 1           | EPI_ISL_15214002 |
|             | 2           | EPI_ISL_15214037 |
| 17          | 1           | EPI_ISL_12687954 |
|             | 2           | EPI_ISL_15214026 |
| 18          | 1           | EPI_ISL_12687959 |
|             | 2           | EPI_ISL_15214043 |
| 19          | 1           | EPI_ISL_15214015 |
|             | 2           | EPI_ISL_15214016 |
| 20          | 1           | EPI_ISL_15214022 |
|             | 2           | EPI_ISL_15214035 |
| 21          | 1           | EPI_ISL_15214023 |
|             | 2           | EPI_ISL_15214036 |
| 22          | 1           | EPI_ISL_15214007 |
|             | 2           | EPI_ISL_15214030 |
| 23          | 1           | EPI_ISL_12688015 |
|             | 2           | EPI_ISL_15214001 |
| 24          | 1           | EPI_ISL_13638547 |
|             | 2           | EPI_ISL_15214034 |
| 25          | 1           | EPI_ISL_15214028 |
|             | 2           | EPI_ISL_15214021 |
| 26          | 1           | EPI_ISL_15214006 |
|             | 2           | ERR10307503      |

\*Sequences deposited in GISAID (<https://www.gisaid.org>) and ENA (<https://www.ebi.ac.uk/ena>). Patients 1–11 had early reinfections; patients 12–22 did not have reinfections (short-term persistence); patients 23–26 had probable reinfections.

**Appendix Table 2.** Sequencing quality values of SARS-CoV-2 in a study of early reinfection involving the same or different genomic lineages, Spain

| Patient no. | Specimen no. | Coverage >30× | Result                 |
|-------------|--------------|---------------|------------------------|
| 1           | 1            | 98.20         | Reinfection            |
|             | 2            | 99.55         | Reinfection            |
| 2           | 1            | 52.55         | Reinfection            |
|             | 2            | 86.95         | Reinfection            |
| 3           | 1            | 38.84         | Reinfection            |
|             | 2            | 99.56         | Reinfection            |
| 4           | 1            | 93.99         | Reinfection            |
|             | 2            | 98.98         | Reinfection            |
| 5           | 1            | 99.30         | Reinfection            |
|             | 2            | 82.90         | Reinfection            |
| 6           | 1            | 65.46         | Reinfection            |
|             | 2            | 99.56         | Reinfection            |
| 7           | 1            | 47.03         | Reinfection            |
|             | 2            | 99.55         | Reinfection            |
| 8           | 1            | 98.10         | Reinfection            |
|             | 2            | 98.55         | Reinfection            |
| 9           | 1            | 97.18         | Reinfection            |
|             | 2            | 75.14         | Reinfection            |
| 10          | 1            | 56.01         | Reinfection            |
|             | 2            | 99.48         | Reinfection            |
| 11          | 1            | 98.53         | Reinfection            |
|             | 2            | 48.80         | Reinfection            |
| 12          | 1            | 96.91         | Short-term persistence |
|             | 2            | 99.53         | Short-term persistence |
| 13          | 1            | 94.56         | Short-term persistence |
|             | 2            | 98.79         | Short-term persistence |
| 14          | 1            | 98.27         | Short-term persistence |
|             | 2            | 96.80         | Short-term persistence |
| 15          | 1            | 98.73         | Short-term persistence |
|             | 2            | 97.31         | Short-term persistence |
| 16          | 1            | 99.17         | Short-term persistence |
|             | 2            | 96.92         | Short-term persistence |
| 17          | 1            | 94.70         | Short-term persistence |
|             | 2            | 46.23         | Short-term persistence |
| 18          | 1            | 97.19         | Short-term persistence |
|             | 2            | 97.31         | Short-term persistence |
| 19          | 1            | 99.48         | Short-term persistence |
|             | 2            | 98.87         | Short-term persistence |
| 20          | 1            | 99.47         | Short-term persistence |
|             | 2            | 97.25         | Short-term persistence |
| 21          | 1            | 99.48         | Short-term persistence |
|             | 2            | 97.90         | Short-term persistence |
| 22          | 1            | 98.63         | Short-term persistence |
|             | 2            | 57.76         | Short-term persistence |
| 23          | 1            | 99.60         | Probable reinfection   |
|             | 2            | 98.71         | Probable reinfection   |
| 24          | 1            | 99.58         | Probable reinfection   |
|             | 2            | 48.28         | Probable reinfection   |
| 25          | 1            | 72.42         | Probable reinfection   |
|             | 2            | 98.70         | Probable reinfection   |
| 26          | 1            | 99.43         | Probable reinfection   |
|             | 2            | 28.40         | Probable reinfection   |



**Appendix Table 3.** Sequencing coverages obtained for the differential SNVs involved in the probable reinfections in a study of early reinfection involving the same or different genomic lineages, Spain\*

| Pt no. | Spec. 1 | Unique SNVs | Spec. 2 | Unique SNVs | Specimen 1 |           |           |        | Specimen 2 |           |           |        |
|--------|---------|-------------|---------|-------------|------------|-----------|-----------|--------|------------|-----------|-----------|--------|
|        |         |             |         |             | POS        | ALT_ FREQ | TOTAL_ DP | Gene   | POS        | ALT_ FREQ | TOTAL_ DP | Gene   |
| 23     | BA.2    | 4           | BA.2    | 4           | 1143       | 0.9991    | 2398      | ORF1ab | 21721      | 0.8238    | 477       | ORF1ab |
|        |         |             |         |             | 5312       | 0.8581    | 2581      | ORF1ab | 22326      | 0.9870    | 155       | S      |
|        |         |             |         |             | 22458      | 0.9564    | 1585      | S      | 22792      | 0.9098    | 255       | S      |
|        |         |             |         |             | 27731      | 0.9975    | 2847      | ORF7a  | 25352      | 0.8310    | 373       | S      |
| 24     | BA.1.1  | 1           | BA.1.1  | 5           | 5386       | 1.0       | 724       | ORF1ab | 13550      | 0.9791    | 192       | ORF1ab |
|        |         |             |         |             |            |           |           |        | 22987      | 0.9753    | 81        | S      |
|        |         |             |         |             |            |           |           |        | 22993      | 0.9638    | 83        | S      |
|        |         |             |         |             |            |           |           |        | 24917      | 0.9401    | 384       | S      |
|        |         |             |         |             |            |           |           |        | 27899      | 0.9860    | 358       | ORFB   |
| 25     | BA.1.17 | 1           | BA.1.17 | 3           | 26916      | 0.7123    | 73        | M      | 11282      | 0.9217    | 2263      | ORF1ab |
|        |         |             |         |             |            |           |           |        | 21762      | 0.9970    | 687       | S      |
|        |         |             |         |             |            |           |           |        | 21764      | 0.9911    | 1014      | S      |
| 26     | BA.2    | 2           | †       | 4           | 17410      | 0.9990    | 1072      | ORF1ab | 868        | 0.9852    | 610       | ORF1ab |
|        |         |             |         |             | 25584      | 0.9990    | 1096      | ORF3a  | 11110      | 1.0       | 2204      | ORF1ab |
|        |         |             |         |             |            |           |           |        | 22689      | 1.0       | 723       | S      |
|        |         |             |         |             |            |           |           |        | 25665      | 1.0       | 1174      | ORF3a  |

\*DP, coverage depth; FREQ, frequency; ORF, open reading frame; POS, position; Pt, patient; S, spike; SNVs, single nucleotide variants; Spec., specimen.

†Unassigned.